Apoptosis, proliferation, and Fas (APO-I, CD95)/Fas ligand expression in medullary carcinoma of the breast

被引:0
|
作者
Yakirevich, E
Maroun, L
Cohen, O
Izhak, OB
Rennert, G
Resnick, MB
机构
[1] Lady Davis Carmel Med Ctr, Dept Pathol, IL-34362 Haifa, Israel
[2] Rambam Med Hosp, Dept Pathol, Haifa, Israel
[3] Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel
[4] Lady Davis Carmel Med Ctr, Dept Surg, IL-34362 Haifa, Israel
[5] Lady Davis Carmel Med Ctr, Dept Community Med & Epidemiol, IL-34362 Haifa, Israel
来源
JOURNAL OF PATHOLOGY | 2000年 / 192卷 / 02期
关键词
breast; medullary carcinoma; apoptosis; TUNEL; proliferation; PCNA; Fas; FasL;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Medullary carcinoma (MC) of the breast is a unique subtype of infiltrating ductal carcinoma that is characterized by a prominent lymphoid infiltrate and improved prognosis. Activated granzyme B+/CD8(+) cytotoxic T-lymphocytes (CTLs) infiltrating tumour cell nests constitute a major subset within the lymphoid infiltrate. As CTLs destroy target tumour cells by triggering apoptosis, it mould be of interest to determine whether the apoptotic rate in MC is increased. This study evaluates the extent of apoptosis in relation to Fas (APO-1, CD95)/Fas ligand (FasL) expression in MC. Fourteen cases of typical MC (TMC) and 15 cases of atypical MC (AMC) classified according to the Ridolfi criteria, as well as 19 cases of poorly differentiated infiltrating ductal carcinoma (PDC) were evaluated. The apoptotic index (AI) was assessed by the TUNEL method on paraffin-embedded tissue. Cell proliferation was evaluated immunohistochemically by PCNA staining. The level of Fas/FasL expression was determined semiquantitatively by immunohistochemistry using a four-grade scoring system. The AI was significantly increased in TMC and AMC as opposed to the PDC subgroup (2.2 +/- 0.8, 2.1 +/- 0.8, and 1.3 +/- 0.6, respectively; p < 0.05). A significant proportion (31.8 +/- 7.9% in TMC and 25.8 +/- 9.7% in AMC) of the apoptotic tumour cells within tumour nests mere in close contact with CD3(+) lymphocytes. Increased apoptosis was not accompanied by increased proliferation of tumour cells. The extent of Fas expression did not differ between the three subgroups. FasL was expressed both by tumour infiltrating lymphocytes in MC and by tumour epithelium in all three subgroups. The observation that the majority of MCs express Fas and are infiltrated by lymphocytes expressing FasL suggests that increased apoptosis in MC is mediated by Fas/FasL. However, our observation that the majority of MCs also express Fast and the fact that tumours co-expressing Fas and FasL did not show increased apoptosis suggest that there may be additional cytotoxic pathways that lead to tumour apoptosis in MC. Copyright (C) 2000 John Wiley & Sons, Ltd.
引用
收藏
页码:166 / 173
页数:8
相关论文
共 50 条
  • [31] Evaluation of CD95 (APO-1/FAS) and the CD95 ligand in acute myelogenous leukemia
    Mestice, A
    Specchia, G
    Coppi, MR
    Palumbo, G
    Carluccio, P
    Attolico, I
    Quarta, A
    Liso, V
    EXPERIMENTAL HEMATOLOGY, 1997, 25 (08) : 74 - 74
  • [32] Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance
    Koomägi, R
    Volm, M
    INTERNATIONAL JOURNAL OF CANCER, 1999, 84 (03) : 239 - 243
  • [33] Expression of Fas (CD95/APO-1) and Fas Ligand (FasL) in Experimentally-Induced Acute Pancreatitis
    Pardalis, Vassilios
    Palli, Eleni
    Lambropoulou, Maria
    Tsigalou, Christina
    Anagnostoulis, Stavros
    Garoufalis, Grigorios
    Bolanaki, Helen
    Simopoulos, Constantinos
    Karayiannakis, Anastasios J.
    JOURNAL OF INVESTIGATIVE SURGERY, 2014, 27 (02) : 65 - 72
  • [34] Regulation of Fas (APO-1, CD95) and Fas ligand expression in leukocytes during systemic inflammation in humans
    Marsik, C
    Halama, T
    Cardona, F
    Wlassits, W
    Mayr, F
    Pleiner, J
    Jilma, B
    SHOCK, 2003, 20 (06): : 493 - 496
  • [35] Expression of Fas (APO-1/CD95) and Fas ligand in astrocytic brain tumors and the mechanisms of necrogenesis in glioblastomas
    Ohgaki, H
    Gratas, C
    Tohma, Y
    Tachibana, O
    Kleihues, P
    BRAIN PATHOLOGY, 1997, 7 (04) : 1183 - 1183
  • [36] Fas (APO-1/CD95) ligand and Fas expression in renal cell carcinomas - Correlation with the prognostic factors
    Kim, YS
    Kim, KE
    Choi, JA
    Lee, JH
    Kim, HK
    Won, NH
    Kim, I
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2000, 124 (05) : 687 - 693
  • [37] Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: Implications for the regulation of apoptosis in neutrophils
    Liles, WC
    Kiener, PA
    Ledbetter, JA
    Aruffo, A
    Klebanoff, SJ
    JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (02): : 429 - 440
  • [38] Fas/APO-1 (CD95) expression in myelodysplastic syndromes
    Lepelley, P
    Grardel, N
    Erny, O
    Iaru, T
    Obein, V
    Cosson, A
    Fenaux, P
    LEUKEMIA & LYMPHOMA, 1998, 30 (3-4) : 307 - 312
  • [39] Expression of Fas (CD95) and Fas ligand in airways of subjects with fatal asthma.
    Dorscheid, DR
    Wilson, SJ
    Conforti, A
    Rabe, KF
    Holgate, ST
    White, SR
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (03) : A440 - A440
  • [40] Sensitivity and resistance to apoptosis in the APO-1 (Fas/CD95) system
    Debatin, KM
    ONKOLOGIE, 1996, 19 : 3 - 5